Company Overview
Evolus, Inc. operates as a performance beauty company dedicated to delivering products within the cash-pay aesthetic market across the United States, Canada, Europe, and Australia. The firm specifically offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation designed for the temporary improvement in the appearance of moderate facial wrinkles. This business model places Evolus, Inc. firmly within the Healthcare sector, specifically under the industry classification of Drug Manufacturers - Specialty & Generic, which defines its focus on developing and commercializing specialized pharmaceutical compounds rather than mass-market generics. The company's current market capitalization stands at $284.31M, supported by an annual revenue of $297.18M and a workforce of 334 employees. These valuation and revenue figures indicate that Evolus, Inc. holds a mid-cap position in the specialty drug landscape, suggesting a significant but not dominant footprint relative to large-cap pharmaceutical peers, while the specific scale of 334 employees reflects a lean operational structure typical of high-margin biologic manufacturers.
Financial Health
The company reported a revenue of $297.18M over the trailing twelve months, yet it recorded a net income of $-51,641,000 and an EBITDA of $-30,094,000. The substantial gap between the positive revenue figure and the negative net income reveals a cost structure where operating expenses, likely driven by research and development or commercialization costs in the aesthetic market, significantly erode profitability before taxes. Free cash flow stands at $-26,697,750, which indicates that the company is currently burning cash, thereby limiting its immediate financial flexibility to fund operations without external financing or cash reserves. Gross margin is reported at 66.3%, which suggests a high level of efficiency in manufacturing the botulinum toxin products relative to sales revenue, while the operating margin of -0.3% and profit margin of -17.4% highlight that general and administrative expenses are outpacing gross profits. Despite the negative earnings, the company holds $53.83M in cash against $155.00M in debt, resulting in a debt-to-equity ratio of N/A which precludes a traditional leverage analysis due to the equity position. The balance sheet appears leveraged by the magnitude of debt relative to cash, though the negative equity further complicates the assessment of conservative financial positioning. Current ratio is 1.90, indicating that the company possesses $1.90 in current assets for every $1.00 of current liabilities, which suggests adequate short-term liquidity to cover immediate obligations. Return on Equity is N/A and Return on Assets is -10.3%, revealing that management effectiveness in generating returns on the capital base is currently negative due to the cumulative losses impacting the equity denominator.
Valuation Assessment
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is 18.21, implying that the market prices the stock based on projected future profitability rather than current historical performance. The price-to-book ratio is -12.31, which indicates that the market values the company at a significant discount to its book value, a common metric for distressed or unprofitable firms where the market premium over book value is negative. Alternative valuation metrics such as a price-to-sales ratio of 0.96 and an EV/EBITDA of -12.81 suggest that investors are valuing the entity primarily on its revenue generation capability rather than earnings power. The stock has traded between a 52-week high of $13.18 and a 52-week low of $4.09, meaning the current market price sits well below the recent peak and within the lower half of the historical trading range observed over the last year. The beta value of 1.01 indicates that the stock's price volatility moves in tandem with the broader market, offering no significant hedge against or amplification of systemic market risks.
Growth & Income
Revenue growth year-over-year is 14.4%, while earnings growth is N/A due to the absence of positive net income in the prior period. Since earnings are not growing in a traditional sense due to losses, the revenue expansion suggests top-line traction, but the inability to convert this into earnings growth implies that cost containment or scaling efficiencies are yet to be achieved. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute dividends to shareholders. This non-dividend status is consistent with the company reinvesting any available cash reserves into research, development, or market expansion rather than paying out income to investors. The overall growth and income profile is characterized by strong revenue expansion offset by significant operating losses and an absence of current income distributions.